1-13 of 13
Peter B. Jensen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors

Ulrik Lassen, Morten Mau-Sørensen, Ulla Hald Buhl, Mogens W. Madsen, Eva Balslev, Dick Pluim, Jan H. M. Schellens, Steen Knudsen, Peter B. Jensen
Journal: Cancer Research
Cancer Res (2016) 76 (14_Supplement): CT154.
https://doi.org/10.1158/1538-7445.AM2016-CT154
Published: 15 July 2016
View articletitled, Abstract CT154: Phase I dose-escalating PoC study to evaluate the safety and tolerability of LiPlaCis (liposomal cisplatin formulation) in patients with advanced or refractory tumors
Journal Articles

SAR analysis of substituted purines as topoisomerase II inhibitors identifies ATPase inhibitors with nanomolar activity.

Lars H. Jensen, Peter B. Jensen, Robert H. Shoemaker, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1301.
Published: 15 April 2006
View articletitled, SAR analysis of substituted purines as topoisomerase II inhibitors identifies ATPase inhibitors with nanomolar activity.
Journal Articles

A transgenic mouse model for analyzing the role of topoisomerase II in mediating the pharmacological effects of dexrazoxane.

Morten Grauslund, Annemette V. Thougaard, Annette Füchtbauer, Kenneth F. Hofland, Peter Hjorth, Seppo Langer, Peter B. Jensen, Lars H. Jensen, Ernst-Martin Füchtbauer, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1298.
Published: 15 April 2006
View articletitled, A transgenic mouse model for analyzing the role of topoisomerase II in mediating the pharmacological effects of dexrazoxane.
Journal Articles

Substituted Purine Analogues Define a Novel Structural Class of Catalytic Topoisomerase II Inhibitors

Lars H. Jensen, Annemette V. Thougaard, Morten Grauslund, Birgitte Søkilde, Elisabeth V. Carstensen, Henrik K. Dvinge, Dominic A. Scudiero, Peter B. Jensen, Robert H. Shoemaker, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2005) 65 (16): 7470–7477.
https://doi.org/10.1158/0008-5472.CAN-05-0707
Published: 15 August 2005
View articletitled, Substituted Purine Analogues Define a Novel Structural Class of Catalytic Topoisomerase II Inhibitors
Open the PDF for Substituted Purine Analogues Define a Novel Structural Class of Catalytic Topoisomerase II Inhibitors in another window
Journal Articles

Malignant transformation of wild type but not plasminogen activator inhibitor-1 gene deficient fibroblasts decreases cellular sensitivity to chemotherapy mediated apoptosis

Ulrik A. Lademann, Maria U. Romer, Nils Brünner, Peter B. Jensen, Kenneth F. Hofland, I. B. J. Christensen
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 195.
Published: 01 May 2005
View articletitled, Malignant transformation of wild type but not plasminogen activator inhibitor-1 gene deficient fibroblasts decreases cellular sensitivity to chemotherapy mediated apoptosis
Journal Articles

Development of resistance in the murine leukemia cell-line P388 towards the hydroxamate histone deacetylase inhibitor PXD101

Torsten H. Nielsen, Nick Edwards, Marielle Dejligbjerg, Mike Jeffers, Peter B. Jensen, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 423–424.
Published: 01 May 2005
View articletitled, Development of resistance in the murine leukemia cell-line P388 towards the hydroxamate histone deacetylase inhibitor PXD101
Journal Articles

A C6-substituted guanine analog defines a novel class of ATP catalytic topoisomerase II inhibitors

Lars H. Jensen, Annemette Tuogaard, Birgitte Sokilde, Henrik K. Dvinge, Morten Grauslund, Elisabeth V. Carstensen, Eric Santoni-Rugiu, Dominic A. Scudiero, Robert H. Shoemaker, Peter B. Jensen, Maxwell Sehested
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 933–934.
Published: 01 May 2005
View articletitled, A C6-substituted guanine analog defines a novel class of ATP catalytic topoisomerase II inhibitors
Journal Articles

Dexrazoxane does not affect pharmacokinetics of high-dose etoposide in patients with brain metastases

Kenneth F. Hofland, Henrik Dvinge, Jette Tjørnelund, Birgitte Søkilde, Maxwell Sehested, Peter B. Jensen
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 941–942.
Published: 01 May 2005
View articletitled, Dexrazoxane does not affect pharmacokinetics of high-dose etoposide in patients with brain metastases
Journal Articles

Cerebral chemo-radiotherapy with etoposide and dexrazoxane increase survival in mice with brain-tumour

Kenneth F. Hofland, Maxwell Sehested, Paul E. G. Kristjansen, Annemette V. Thougaard, Pia Rengtved, Peter B. Jensen
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 313.
Published: 01 April 2004
View articletitled, Cerebral chemo-radiotherapy with etoposide and dexrazoxane increase survival in mice with brain-tumour
Journal Articles

Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the α Isoform

Irene Wessel, Lars H. Jensen, Peter B. Jensen, Jacob Falck, Angela Rose, Mikael Roerth, John L. Nitiss, Maxwell Sehested
Journal: Cancer Research
Cancer Res (1999) 59 (14): 3442–3450.
Published: 15 July 1999
View articletitled, Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the α Isoform
Open the PDF for Human Small Cell Lung Cancer NYH Cells Selected for Resistance to the Bisdioxopiperazine Topoisomerase II Catalytic Inhibitor ICRF-187 Demonstrate a Functional R162Q Mutation in the Walker A Consensus ATP Binding Domain of the α Isoform in another window
Journal Articles

Chinese Hamster Ovary Cells Resistant to the Topoisomerase II Catalytic Inhibitor ICRF-159: A Tyr49Phe Mutation Confers High-Level Resistance to Bisdioxopiperazines

Maxwell Sehested, Irene Wessel, Lars H. Jensen, Bente Holm, Roberto S. Oliveri, Sue Kenwrick, Andrew M. Creighton, John L. Nitiss, Peter B. Jensen
Journal: Cancer Research
Cancer Res (1998) 58 (7): 1460–1468.
Published: 01 April 1998
View articletitled, Chinese Hamster Ovary Cells Resistant to the Topoisomerase II Catalytic Inhibitor ICRF-159: A Tyr49Phe Mutation Confers High-Level Resistance to Bisdioxopiperazines
Open the PDF for Chinese Hamster Ovary Cells Resistant to the Topoisomerase II Catalytic Inhibitor ICRF-159: A Tyr49Phe Mutation Confers High-Level Resistance to Bisdioxopiperazines in another window
Journal Articles

Loss of Amino Acids 1490Lys-Ser-Lys1492 in the COOH-Terminal Region of Topoisomerase IIα in Human Small Cell Lung Cancer Cells Selected for Resistance to Etoposide Results in an Extranuclear Enzyme Localization

Irene Wessel, Peter B. Jensen, Jacob Falck, Shelagh E. L. Mirski, Susan P. C. Cole, Maxwell Sehested
Journal: Cancer Research
Cancer Res (1997) 57 (20): 4451–4454.
Published: 01 October 1997
View articletitled, Loss of Amino Acids 1490Lys-Ser-Lys1492 in the COOH-Terminal Region of Topoisomerase IIα in Human Small Cell Lung Cancer Cells Selected for Resistance to Etoposide Results in an Extranuclear Enzyme Localization
Open the PDF for Loss of Amino Acids 1490Lys-Ser-Lys1492 in the COOH-Terminal Region of Topoisomerase IIα in Human Small Cell Lung Cancer Cells Selected for Resistance to Etoposide Results in an Extranuclear Enzyme Localization in another window
Journal Articles

Sequential Coexpression of the Multidrug Resistance Genes MRP and mdr1 and Their Products in VP-16 (Etoposide)-selected H69 Small Cell Lung Cancer Cells

Inger Brock, David R. Hipfner, Boye S. Nielsen, Peter B. Jensen, Roger G. Deeley, Susan P. C. Cole, Maxwell Sehested
Journal: Cancer Research
Cancer Res (1995) 55 (3): 459–462.
Published: 01 February 1995
View articletitled, Sequential Coexpression of the Multidrug Resistance Genes MRP and mdr1 and Their Products in VP-16 (Etoposide)-selected H69 Small Cell Lung Cancer Cells
Open the PDF for Sequential Coexpression of the Multidrug Resistance Genes MRP and mdr1 and Their Products in VP-16 (Etoposide)-selected H69 Small Cell Lung Cancer Cells in another window